 Home > Medical News > Latest Medical News > Janssen Amivantamab was approved to be marketed as the world's first bispecific antibody for the treatment of NSCLC

Janssen Amivantamab was approved to be marketed as the world's first bispecific antibody for the treatment of NSCLC

 Last Update: 2021-06-08
 Source: Internet
 Author: User

Tags

humidity data logger

pd 1 cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Amivantamab (Rybrevant®) developed by Janssen Bio is a bispecific antibody targeting c-MET/HGFR and EGFR.

Lung cancer is the most common type of tumor, and it is also a tumor with high mortality worldwide.

Amivantamab was approved based on a multi-center, open-label, multi-cohort trial that included 81 NSCLC patients with EGFR exon 20 insertion mutations.

The details of Amivantamab and the double antibody drugs targeting c-MET/HGFR and EGFR are shown in the figure below:

Reference

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

[One picture, one drug] Janssen Amivantamab was approved for marketing, the world's first bispecific antibody for the treatment of NSCLC

06-05

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Janssen Amivantamab was approved to be marketed as the world's first bispecific antibody for the treatment of NSCLC

Related Articles

[One picture, one drug] Janssen Amivantamab was approved for marketing, the world's first bispecific antibody for the treatment of NSCLC